Medicine company – Clomiphene QB http://clomipheneqb.com/ Tue, 11 Jan 2022 13:22:52 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://clomipheneqb.com/wp-content/uploads/2021/10/cropped-icon-32x32.png Medicine company – Clomiphene QB http://clomipheneqb.com/ 32 32 Perth-based regenerative medicine company Orthocell created the procedure, known as Ortho-ATI. https://clomipheneqb.com/perth-based-regenerative-medicine-company-orthocell-created-the-procedure-known-as-ortho-ati/ Fri, 10 Dec 2021 11:37:01 +0000 https://clomipheneqb.com/perth-based-regenerative-medicine-company-orthocell-created-the-procedure-known-as-ortho-ati/
Perth doctors have created a non-invasive, non-surgical solution to help heal chronic tendon injuries.

Perth-based regenerative medicine company Orthocell created the procedure, known as Ortho-ATI.

First, it is a small tendon biopsy taken from a healthy area and transferred to a laboratory.

Doctors in Perth have created a non-invasive, non-surgical solution to chronic tendon injuries. (9News)

There, the tendon’s stem cells are nourished, growing from thousands of cells to millions.

They are then injected into the injury site, allowing new, healthy tendons to rebuild.

“It’s a minimally invasive approach to healing chronic tendon injuries,” said Orthocell CEO Paul Anderson.

Perth-based regenerative medicine company called Ortho Cell created the procedure, known as OrthoAti.
Perth-based regenerative medicine company called Ortho Cell created the procedure, known as OrthoAti. (9News)

The cells can be stored in the laboratory for up to 20 years and used for future injuries.

Currently, the treatment is only available to patients in clinical trials and is pending approval by the Therapeutic Goods Administration.

West Coast Eagles player Mark LeCras is one of the patients who received the treatment.

West Coast Eagles player Mark LeCras is one of the patients who received the treatment.
West Coast Eagles player Mark LeCras is one of the patients who received the treatment. (9News)

The AFL star nearly lost his career after a nasty knee tendon injury that plagued him for 12 months.

“We’ve tried a few different therapies to try and fix it, but we haven’t really done it,” LeCras said. “It completely healed me.”

He has since played eight more seasons which even included a Premiership victory.

Source link

]]>
Next Generation Precision Medicine Company Allorion Therapeutics Completes Series A Funding Round https://clomipheneqb.com/next-generation-precision-medicine-company-allorion-therapeutics-completes-series-a-funding-round-2/ Wed, 24 Nov 2021 08:00:00 +0000 https://clomipheneqb.com/next-generation-precision-medicine-company-allorion-therapeutics-completes-series-a-funding-round-2/

Focus on the discovery and development of small molecule drugs for cancer and autoimmune diseases

BOSTON, November 24, 2021 / PRNewswire / – Allorion Therapeutics, a company specializing in next-generation precision medicine for oncology and autoimmune diseases, today announced the completion of $ 40 million Series A financing. This funding round is led by Qiming Venture Partners and participated by IDG Capital, Octagon Capital, Firstred Capital and Elikon Venture. Existing investors – TF Capital and Med-Fine Capital – continued to support this round.

The product will be used to support Allorion’s preclinical projects, IND studies and IND applications of two drug candidates in China and United States. Allorion will also increase its investment in its platform technologies in the systematic screening of allosteric inhibitors and synthetic lethality targets with corresponding tool compounds and strengthen the clinical and commercial development teams.

Allorion’s Drug Discovery Engine integrates technological advances in protein structure, big data, machine learning and gene editing to systematically discover and develop highly selective small molecules, including covalent and allosteric inhibitors well validated targets. Allorion has also built a unique synthetic lethality screening platform to expand the reach of targeted therapies for cancer patients, thus laying a solid foundation for the long-term success of the company. Allorion strives to select targets and execute projects and meets high standards in drug discovery and data quality to achieve international recognition and collaboration.

Peter Ding, Founder and CEO of Allorion Therapeutics, said: “On last year, Allorion developed R&D capabilities in Boston and Canton and formed a strong management and R&D team. Several projects have reached their milestones. The completion of this round table shows the recognition by investors of the progress and support for the long-term strategy of the company on highly innovative platforms for the discovery of best or first-in-class drugs. We thank all investors for their trust and support. We will continue our efforts to promote innovative small molecule drugs in clinical research, thereby meeting unmet clinical needs. Allorion will leverage cutting-edge technologies and strive to make precision medicine more precise and accessible to more patients. “

Chen Kan, Director of Qiming Venture Partners, said, “There are huge unmet medical needs for autoimmune diseases and cancer treatment around the world. Based on data mining and a deep understanding of disease biology, Allorion is focused on the early discovery and development of precision drugs. We have confidence in the strong R&D capabilities of the team. We hope to help Allorion become a globally recognized company and improve the quality of life for patients.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leader China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Currently, Qiming Venture Partners manages ten american dollars funds and six RMB funds with $ 6.2 billion outstanding under raised capital. Since its inception, Qiming Venture Partners has invested in outstanding TMT and healthcare companies in start-up and growth stages. Since its inception, Qiming Venture Partners has supported more than 430 innovative and fast growing companies. Over 170 companies are already listed on the NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or have successfully exited through mergers and acquisitions and other means . There are also over 40 portfolio companies that have achieved unicorn status.

About TF Capital

TF Capital focuses on investing in the life sciences sector, investing primarily in high potential start-ups. Through strategic investments in various key areas and good partnerships, TF Capital hopes to seize opportunities in the growing Chinese life sciences market. Our investment team has extensive industry experience and resources to assist our portfolio companies.

Cision

Show original content:https://www.prnewswire.com/news-releases/next-generation-precision-medicine-company-allorion-therapeutics-completes-series-a-financing-round-301431451.html

SOURCE Allorion Therapeutics

Source link

]]>
Next Generation Precision Medicine Company Allorion Therapeutics Completes Series A Funding Round https://clomipheneqb.com/next-generation-precision-medicine-company-allorion-therapeutics-completes-series-a-funding-round/ Wed, 24 Nov 2021 08:00:00 +0000 https://clomipheneqb.com/next-generation-precision-medicine-company-allorion-therapeutics-completes-series-a-funding-round/

BOSTON, November 24, 2021 / PRNewswire / – Allorion Therapeutics, a company specializing in next-generation precision medicine for oncology and autoimmune diseases, today announced the completion of $ 40 million Series A financing. This funding round is led by Qiming Venture Partners and participated by IDG Capital, Octagon Capital, Firstred Capital and Elikon Venture. Existing investors – TF Capital and Med-Fine Capital – continued to support this round.

Proceeds from the sale will be used to support Allorion’s preclinical projects, IND studies and IND applications of two drug candidates in China and United States. Allorion will also increase its investment in its platform technologies in the systematic screening of allosteric inhibitors and synthetic lethality targets with corresponding tool compounds and strengthen the clinical and commercial development teams.

Allorion’s Drug Discovery Engine integrates technological advances in protein structure, big data, machine learning and gene editing to systematically discover and develop highly selective small molecules, including covalent and allosteric inhibitors well validated targets. Allorion has also built a unique synthetic lethality screening platform to expand the reach of targeted therapies for cancer patients, thus laying a solid foundation for the long-term success of the company. Allorion strives to select targets and execute projects and meets high standards of drug discovery and data quality to achieve international recognition and collaboration.

Peter Ding, Founder and CEO of Allorion Therapeutics, said: “On last year, Allorion developed R&D capabilities in Boston and Canton and formed a strong management and R&D team. Several projects have reached their milestones. The completion of this round table shows the recognition by investors of the progress and support for the long-term strategy of the company on highly innovative platforms for the discovery of best or first-in-class drugs. We thank all investors for their trust and support. We will continue our efforts to promote innovative small molecule drugs in clinical research, thereby meeting unmet clinical needs. Allorion will leverage cutting-edge technologies and strive to make precision medicine more precise and accessible to more patients. “

Chen Kan, Director of Qiming Venture Partners, said, “There are huge unmet medical needs for autoimmune diseases and cancer treatment around the world. Based on data mining and a deep understanding of disease biology, Allorion is focused on the early discovery and development of precision drugs. We have confidence in the strong R&D capabilities of the team. We hope to help Allorion become a globally recognized company and improve the quality of life for patients.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leader China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Currently, Qiming Venture Partners manages ten american dollars funds and six RMB funds with $ 6.2 billion outstanding under raised capital. Since its inception, Qiming Venture Partners has invested in outstanding TMT and healthcare companies in start-up and growth stages. Since its inception, Qiming Venture Partners has supported more than 430 innovative and fast growing companies. Over 170 companies are already listed on the NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or have successfully exited through mergers and acquisitions and other means . There are also over 40 portfolio companies that have achieved unicorn status.

About TF Capital

TF Capital focuses on investing in the life sciences sector, investing primarily in high potential start-ups. Through strategic investments in various key areas and good partnerships, TF Capital hopes to seize opportunities in the growing Chinese life sciences market. Our investment team has extensive industry experience and resources to assist our portfolio companies.

SOURCE Allorion Therapeutics

Source link

]]>
Perrigo buys European drug company for around $ 2 billion https://clomipheneqb.com/perrigo-buys-european-drug-company-for-around-2-billion/ https://clomipheneqb.com/perrigo-buys-european-drug-company-for-around-2-billion/#respond Wed, 08 Sep 2021 07:00:00 +0000 https://clomipheneqb.com/perrigo-buys-european-drug-company-for-around-2-billion/

GRAND RAPIDS, Mich. (WOOD) – West Michigan self-care maker Perrigo plans to spend about $ 2.1 billion to buy European company HRA Pharma.

The purchase is expected to be finalized in the first half of next year, assuming it gets approved by regulators.

Based in Paris HRA Pharma manufactures several over-the-counter blister care, women’s health and scar care products, as well as some specialty drugs for rare diseases. Perrigo says its acquisition is expected to “significantly strengthen (its) global footprint.”

“With the addition of HRA and its talented management team, Perrigo would be a global leader in consumer personal care that is poised to deliver leading net sales growth and double-digit growth (earnings per share ) in the short term while simultaneously developing margins, ”Perrigo President and CEO Murray Kessler said in a statement. “… This is literally a unique opportunity to simultaneously improve our financial profile, while creating even greater value for consumers, shareholders and the communities in which we work and live. “

Perrigo says it expects to save $ 30 million in the first year of the acquisition by combining and streamlining its and HRA operations. He added that the purchase of HRA could increase sales by around $ 400 million in fiscal year 2023.

Perrigo, an over-the-counter giant in the United States, currently has its North American headquarters in Allegan, but is working on relocation of HQ to Grand Rapids,

`)); // Integrated Facebook script (function (d, s, id) {var js, fjs = d.getElementsByTagName (s)[0]; if (d.getElementById (id)) return; js = d.createElement (s); js.id = identifier; js.src = “https://connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.12&appId=166116077300962&autoLogAppEvents=1″; fjs.parentNode.insertBefore (js, fjs); } (document, ‘script’, ‘facebook-jssdk’)); // Integration of the Twitter script (function (d, s, id) {var js, tjs = d.getElementsByTagName (s)[0]; if (d.getElementById (id)) return; js = d.createElement (s); js.id = identifier; js.setAttribute (‘async’, ”); js.src = “https://platform.twitter.com/widgets.js”; tjs.parentNode.insertBefore (js, tjs); } (document, ‘script’, ‘twitter-js’)); } // Simplify some iframe stuff var iframes = $ (‘iframe’); iframes .filter (‘.responsive’) .each (function (_, frame) {// 16×9 responsive ratio iframes var $ frame = $ (frame); $ (frame) .css ({position: ‘absolute’, top: 0, left: 0, right: 0, width: ‘100%’, height: ‘100%’,}). Parent (). AddClass (‘wood-responsive-container wood-responsive-container-16×9’);} ); var lazyFrames = iframes .filter (‘[data-lazy-src]’); function woodMakeLazyFrame (selector) {var observer; var options = {root: null, rootMargin: ‘0px’, threshold: 0,}; function handler (entries, observer) {entries.forEach (function (entry) {var ioR = entry.intersectionRatio; if (ioR> 0) {entry.target.src = entry.target.dataset.lazySrc; observer.unobserve ( entry .target);}}); } observer = new IntersectionObserver (manager, options); observe.observ (selector); } lazyFrames.each ((_, frame) => woodMakeLazyFrame (frame)); }); } (jQuery))

Source link

]]>
https://clomipheneqb.com/perrigo-buys-european-drug-company-for-around-2-billion/feed/ 0
KeevaRX: the world’s first clean dermatological medicine company https://clomipheneqb.com/keevarx-the-worlds-first-clean-dermatological-medicine-company/ https://clomipheneqb.com/keevarx-the-worlds-first-clean-dermatological-medicine-company/#respond Mon, 16 Aug 2021 07:00:00 +0000 https://clomipheneqb.com/keevarx-the-worlds-first-clean-dermatological-medicine-company/

Clean Ingredient Skin & Hair Treatments Doctor Prescribed Online, with Planet Positive packaging delivered right to your door.

Aug 16, 2021 – Keeva Rx is the only acne, anti-aging and hair loss treatment that uses clean ingredients as the basis for their prescriptions. Those who struggle with acne no longer have to seek outside sources for natural based skin care with prescription strength.

These skin care products combine effective active ingredients with clean inactive ingredients in Planet Positive packaging. The company’s goal is to provide the most effective prescription treatments prescribed by licensed physicians.

The products are available exclusively through the company’s telemedicine site. In keeping with the positive planet ethics of the company, they offer unlimited monthly doctor visits online.

The demand for priceless clinical dermatology acne solutions has never been higher. Unlike Curology or Dear Brightly, customers enjoy unlimited online dermatology visits, free and fast shipping, guaranteed 30-day prescription drug supply, no hidden charges, and constant care for all their skin issues. skin care.

According to the American Association of Medical Colleges, the global healthcare industry is responsible for two gigatonnes of carbon dioxide each year, or 4.4% of global net emissions, or the equivalent of 514 coal-fired power plants.

That is why KeevaRX offers personalized care and a mobile approach to dermatology at a fair price. Clients receive unlimited personalized care for less than the average co-payment. It replaces the need for expensive and lengthy trips to a dermatologist’s office, allowing consumers to afford affordable prescription strength treatments without having to leave home.

The KeevaRx team of talented experts, researchers and dermatologists help users control acne, wrinkles and dryness with proven formulas of clean ingredients. The most advanced prescription strength, clinically proven science, and natural infusions create the gentlest skin creams you can find.

Most acne creams and prescription anti-aging creams on the market can dry out your skin, contain toxic ingredients, and cause irritation. Fortunately, KeevaRx products nourish skin and hair while soothing for comfort while healing.

Joe MacLean, Founder of Keeva Rx, says, “KeevaRX offers prescription acne treatments formulated with the cleanest ingredients possible. Prescription acne creams can dry out and irritate your skin. Yes, your acne will go away eventually, but your skin remains red, scaly, and itchy. Plus, the active ingredient in the cream may be as little as 2-5% of what you put on your skin. The remaining 95% of the cream may not contain clean ingredients.

As the climate change crisis continues, Keeva Rx has started to implement environmentally friendly variables in every part of its brand. Being carbon neutral, recyclable and having decomposable packaging was a must. “Nature is part of our skincare formula, which is why we are so passionate about preserving it in the midst of the climate crisis.”

KeevaRx listens to customer feedback to create the best products possible. The team of talented experts, researchers and dermatologists help users control acne, wrinkles and dryness with proven formulas of clean ingredients. The most advanced prescription strength, clinically proven science, and natural infusions create the gentlest skin creams you can find. Customers realize the KeevaRX difference during the first FREE virtual dermatology visit with our medical team. Visits KeevaRx.com to learn more!

About KeevaRx

KeevaRx uses natural skin care ingredients like tea tree oil and lavender for soothing anti-aging effects, along with nutrients proven for hair growth in its topical serum. Get Free Dermatology Visits and Free Shipping Via KeevaRx.com.

Media contact
Company Name: Keeva Rx
Contact: Natalia Szurawski
E-mail: Send an email
Country: United States
Website: https://keevarx.com/

Source link

]]>
https://clomipheneqb.com/keevarx-the-worlds-first-clean-dermatological-medicine-company/feed/ 0
Personalized regenerative medicine company developing implanted cell pockets to treat chronic diseases https://clomipheneqb.com/personalized-regenerative-medicine-company-developing-implanted-cell-pockets-to-treat-chronic-diseases/ https://clomipheneqb.com/personalized-regenerative-medicine-company-developing-implanted-cell-pockets-to-treat-chronic-diseases/#respond Mon, 09 Aug 2021 07:00:00 +0000 https://clomipheneqb.com/personalized-regenerative-medicine-company-developing-implanted-cell-pockets-to-treat-chronic-diseases/

Crystal Nyitray, Ph.D., CEO and Co-Founder of Encellin provided an overview of the company’s emerging cellular technology to treat chronic endocrine disorders, hypoglycemia and hypocalcemia.

Why did you start this business?

Encellin was founded because we have a unique opportunity to help millions of patients. The technology developed at UCSF needed a way forward, so we created Encellin. Starting a business also gives you the opportunity to create a specialized team of people dedicated to advancing therapy. We are creating a culture that cares about helping patients and has the courage to try new ways of thinking.

Nyitray crystal

We recently announced the closure of a $ 5.9 million Seed financing round. The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.

What need are you looking to meet in the health sector?

There are 10,000 billion cells in our body that work to keep us healthy. And when these cells are damaged or missing, patients contract disease. Cellular therapies begin to solve these problems by restoring missing or damaged cell functions. To safely deliver cells to the body, the host must be either:

A) Immune removed so that the foreign tissue can be protected or

B) Dose with an immune protected cell which leaves the recipient unprotected against continuously growing cell lines.

Encellin has developed a way to protect implanted cells and protect the host from unwanted cells. We protect cells and protect humans. With our technology, we can enable cells to be living drugs in the body that can provide therapy when and where it’s needed.

What does your product do? How it works?

Encellin invented a soft cell encapsulation (CED) device that works like a pocket to contain and help cells survive in the body. Encellin’s CED enables closed cells to function as intelligent molecular factories, releasing therapeutic agents when needed. Our new CED allows cells from different sources to be loaded into the CED and implanted into a recipient. Once implanted, cells within the CED are able to maintain their normal function and exchange necessary biomolecules with the host environment to provide therapeutic benefit.

Is this your first healthcare startup? What is your background in the health field?

Encellin is my first startup, but before Encellin, I helped dozens of companies exit UCSF. I was at Sanofi’s External Science and Partnering, and before that, I was doing my PhD. at UCSF where the core Encellin technology was developed. I want to help patients and structure my career in places where I can advance cutting edge technology.

What is your business model?

Encellin is building a pipeline of cell therapies focused on important unmet clinical needs with a clear mechanism of action.

Who is your client?

Our ultimate customer is the patient. However, we will also work with hospitals and payers to ensure these products can be properly covered to ensure accessibility for patients.

How to generate income?

Encellin is developing cell therapies and will follow a standard model of therapeutic revenue generation.

Do you have clinical validation for your product?

Encellin is a preclinical stage company with proof of concept in animals. Our main programs are at the doorstep of the clinic entrance.

Source link

]]>
https://clomipheneqb.com/personalized-regenerative-medicine-company-developing-implanted-cell-pockets-to-treat-chronic-diseases/feed/ 0
Celularity, Clinical-Stage Cellular Medicine Company, Goes Public Following $ 138 Million Merger https://clomipheneqb.com/celularity-clinical-stage-cellular-medicine-company-goes-public-following-138-million-merger/ https://clomipheneqb.com/celularity-clinical-stage-cellular-medicine-company-goes-public-following-138-million-merger/#respond Fri, 16 Jul 2021 07:00:00 +0000 https://clomipheneqb.com/celularity-clinical-stage-cellular-medicine-company-goes-public-following-138-million-merger/ Common shares of the combined company, Celularity, Inc., will begin trading on the Nasdaq Capital Market under the symbol “CELU” on July 19.

Celularity, Inc., a clinical-stage cellular medicine company that develops ready-to-use allogenotherapies derived from the postpartum human placenta, today announced its IPO.

The news comes after the finalization of the merger with GX Acquisition Corp, a specialist acquisition company. The company will operate under the name Celularity, Inc., and effective July 19, the company will begin trading on the Nasdaq Capital Market under the ticker symbol “CELU”.

Proceeds from the transaction totaled approximately $ 138 million, which includes funds held in GXGX’s trust account and a concurrent private placement in the public equity financing led by existing Celularity shareholders. Celularity’s management team will continue to lead the combined company as a result of this transaction.

“Celularity aims to transform the way we approach the treatment of cancer and other diseases by harnessing the versatility, unique immune biology and innate strain of placental-derived cells,” said Robert J. Hariri, MD, Ph. D., Founder, President and CEO of Celularity. “We are extremely proud of our clinical development results to date, as well as the advanced manufacturing capabilities we have built to support rapid scale-up and a competitive cost structure for our cell-derived therapies. of the placenta. We believe that out-of-the-box allogeneic cell therapies will lead to a paradigm shift in the way clinicians approach the treatment of cancer and other serious illnesses.

Hariri added, “Our PIPE is led by existing Celularity investors, who understand the company’s pipeline and clinical development program and have taken the opportunity to add to their investment in Celularity. partnerships with leaders like Palantir and Arthrex which we believe will strengthen our intellectual property and increase revenues from its existing marketed products.

Dean C. Kehler, Co-President and CEO of GX Acquisition Corp. and new Celularity board member, added, “We are delighted to see Celularity take this very important next step in its evolution as a transformative biotech company to become a publicly traded company.

“This step will allow Celularity to continue to leverage the company’s business and clinical assets to treat high unmet need, such as cancer, infectious diseases and degenerative diseases,” he added.

The company’s clinical pipeline includes several clinical stage programs, including acute myeloid leukemia (AML) and glioblastoma multiforme (GBM), with a total of five clinical programs expected by the first half of 2022.

CYNK-001, the Company’s flagship product candidate, is the only cryopreserved, allogeneic, ready-to-use cell therapy to be developed from placental hematopoietic stem cells. The agent expresses perforin and granzyme B, has shown cytotoxic activity against hematologic tumors and solid tumor cell lines, and can secrete immunomodulatory cytokines in the presence of tumor cells.

The new therapy is being explored as a potential option in multiple myeloma, acute myeloid leukemia (AML) and glioblastoma multiforme; it is also evaluated in infectious diseases like COVID-19 (NCT04365101).

Source link

]]>
https://clomipheneqb.com/celularity-clinical-stage-cellular-medicine-company-goes-public-following-138-million-merger/feed/ 0
World’s First and Only Clean Medicine Company Genexa Announces Record Series A Lap https://clomipheneqb.com/worlds-first-and-only-clean-medicine-company-genexa-announces-record-series-a-lap/ https://clomipheneqb.com/worlds-first-and-only-clean-medicine-company-genexa-announces-record-series-a-lap/#respond Wed, 14 Jul 2021 07:00:00 +0000 https://clomipheneqb.com/worlds-first-and-only-clean-medicine-company-genexa-announces-record-series-a-lap/

ATLANTA – (COMMERCIAL THREAD) –Genexa, the world’s first clean, over-the-counter pharmaceutical company, just completed its unprecedented $ 60 million Series A financing to advance its market leadership in this emerging space. Marking a landmark development in consumer healthcare, Genexa’s oversubscribed campaign was the largest Series A ever raised for an over-the-counter drug company, confirming the drastic shift in consumers seeking cleaner options . Initially seeking $ 25 million in capital, Genexa increased the round due to the caliber of investors and celebrities who wanted to be involved in creating a cleaner and more transparent drug aisle.

“Genexa is pioneering a powerful movement that will revolutionize the over-the-counter drug industry in the years to come,” notes Brian perkins, president of Genexa and former global president of Consumer Pharmaceuticals & Nutritionals at Johnson & Johnson. “In an industry ripe for disruption, Genexa is making long-awaited formulation improvements with high-quality ingredients and setting a whole new standard and a whole new level of transparency in over-the-counter drugs. ”

Jared stein, co-founder and managing partner of Monogram capital led the round and was joined by some of the world’s most reputable investors including Unilever Ventures, Verlinvest, Northcastle Partners, and Capital of Pointe King. Joining this group of top investors was an equally powerful roster of celebrity wellness advocates, including Gwyneth Paltrow, Chris Pratt, Katherine schwarzenegger, Donald glover, Lily aldridge, Jennifer meyer, Regina Room, Sanaa Lathan, Don cheadle, Bridgid coulter, Lana parrilla, Patrick schwarzenegger, Tony Kanal, Zoey German, Brandon shainfeld and Angela Fletcher.

“Genexa heralds a radical change in medicine, giving consumers access to the first clean, healthier and efficient option in the over-the-counter market. Consumers have demanded better in every other facet of their lives, and with Genexa, they can finally do the same in their medicine cabinets, ”said the co-founder and managing partner of Monogram Capital. Jared stein. “We couldn’t be more proud to support David and Max’s mission to lead this generational category change. ”

Founded by David johnson and Max Spielberg, two fathers with a personal mission to find better medicines for their families, Genexa offers cleaner and more effective over-the-counter medicines covering all traditional categories of over-the-counter medicines, including pain and fever, colds and flu, as well as digestion and allergies, with products for infants, children and adults alike.

Genexa’s innovative and patented preservation system has allowed the company to set a new global standard for the industry, becoming the brand of choice for consumers seeking a healthier lifestyle. Genexa products contain the same effective active ingredients as the category leaders, but for the first time ever, without the unnecessary and potentially harmful fillers found in most other traditional OTC offerings. Their “Ex List”, the list of unnecessary ingredients often found in other brands that will never appear in Genexa formulas, includes sorbitol, propylene glycol, artificial colors, synthetic binders, talc. and common allergens like gluten and lactose.

Genexa products are available at more than 45,000 retailers nationwide, including Walmart, Target, CVS, Kroger, Target, Walgreens, Whole Foods and Sprouts, as well as online at Genexa.com and Amazon.

Along with pharmaceutical industry veterans like Perkins, the company has assembled a respected medical advisory board of leading experts.

“We did not accept the feedback we received from countless manufacturers who told us that artificial binders and fillers are needed in over-the-counter drugs to keep them stable. a better solution, ”said the co-founders of Genexa Johnson and Spielberg. “Through the innovative products we create and the breakthroughs we have made with over-the-counter medications, we hope to inspire others in the industry to continue our mission of cleaning the medication aisle and delivering solutions. cleaner and healthier for everyone.

All Genexa products are manufactured according to FDA guidelines and are Project Verified for Non-GMOs and Gluten Free. Many are also certified organic and vegan. As a certified B-Corporation, Genexa is committed to using business as a force for good, upholding rigorous standards of social and environmental performance, accountability and transparency.

For more information visit Genexa.com.

ABOUT GENEXA:

Founded by two fathers with the goal of revolutionizing the drug aisle, Genexa makes drugs with the same active ingredients people need, but without the artificial ingredients they don’t have. We believe people deserve better. That’s why our business is built on a commitment to put people first. All of our products are made to the highest medical standards, with no artificial colors, common allergens or unnecessary inactive ingredients. It’s real medicine, made clean. Find out how we put people above everything, in everything we do, at Genexa.com.

ABOUT THE CAPITAL MONOGRAM:

Based in Los Angeles, California and founded in 2014, Monogram Capital Partners focuses exclusively on investing in high-growth consumer and omnichannel brands with more than $ 500 million in capital under management. The company seeks to partner with strong founders and leadership teams, supporting category-leading brands including Chewy.com, Oatly, Country Archer, Olipop, Vive Organic and Foxtrot. Genexa represents the twenty-eighth company in the firm’s portfolio. To learn more about Monogram, please visit: www.monogramcapital.com.

Source link

]]> https://clomipheneqb.com/worlds-first-and-only-clean-medicine-company-genexa-announces-record-series-a-lap/feed/ 0 Philip Morris buys inhalation drug company for $ 1.2 billion in health campaign https://clomipheneqb.com/philip-morris-buys-inhalation-drug-company-for-1-2-billion-in-health-campaign/ https://clomipheneqb.com/philip-morris-buys-inhalation-drug-company-for-1-2-billion-in-health-campaign/#respond Fri, 09 Jul 2021 07:00:00 +0000 https://clomipheneqb.com/philip-morris-buys-inhalation-drug-company-for-1-2-billion-in-health-campaign/

Philip Morris said the acquisition is part of his move into a larger healthcare and wellness company.


Photo:

Fabrice Coffrini / Agence France-Presse / Getty Images

Philip Morris International Inc.

PM 0.69%

has agreed to buy Vectura Group PLC, a UK pharmaceutical company specializing in inhaled drugs, for $ 1.24 billion in cash, further strengthening its drive to grow beyond tobacco and nicotine.

Philip Morris International, which is listed in New York but sells the Marlboro brand outside the United States, said on Friday that Vectura would be the backbone of a business built around inhalation therapy. Inhalers used by asthmatics, for example, are common for the treatment of respiratory diseases, but have shown promise for the administration of other drugs.

The deal trumps a previous deal Vectura struck in May to be acquired by Carlyle Group Inc. Philip Morris’ £ 899.2million offer values ​​Vectura at 150p per share, 10% more than the offer of the private equity firm. Carlyle said on Friday he was considering his options.

Vectura shares were trading up 13% in London.

Philip Morris said the acquisition is part of his move into a larger healthcare and wellness company. Earlier this year, it announced plans to generate more than half of its revenue from smokeless products by 2025, up from 24% in 2020.

Philip Morris said the administration of respiratory medications and so-called self-care wellness products are essential in his plans to move away from tobacco and nicotine. He said Vectura can help him tap into the rapidly growing market for inhalation therapeutics.

Vectura, based in Chippenham, England, will operate as a stand-alone business unit within Philip Morris with the support of its current strategy, the companies said. In 2019, the company changed its strategy to focus on providing contract drug development services for its partners.

Copyright © 2021 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Appeared in the print edition of July 10, 2021 under the title “Philip Morris Bids for Drug Firm”.

Source link

]]>
https://clomipheneqb.com/philip-morris-buys-inhalation-drug-company-for-1-2-billion-in-health-campaign/feed/ 0
Meet the founders of Genexa, the 1st ‘Clean Medicine Company’ https://clomipheneqb.com/meet-the-founders-of-genexa-the-1st-clean-medicine-company/ https://clomipheneqb.com/meet-the-founders-of-genexa-the-1st-clean-medicine-company/#respond Tue, 29 Jun 2021 07:00:00 +0000 https://clomipheneqb.com/meet-the-founders-of-genexa-the-1st-clean-medicine-company/

Us Weekly has affiliate partnerships, so we may receive compensation for certain links to products and services.

For generations, families have searched the drug aisle for products without looking at the ingredients. They took an over-the-counter medicine and never thought about what was inside; the only thing that mattered was that it relieved the condition being treated. Why would they do it? It’s easy to think that trusted pharmaceutical companies would create safe, effective, and healthy products for everyone.

When the founders of Genexa looked around the drug aisle they found something they really weren’t comfortable with: tons of man-made fillers that included common allergens, parabens, and an assortment of synthetic ingredients that they didn’t not wanted in the bodies of their children.

Meet the founders of the first clean medicine company, David Johnson and Max Spielberg. These two dads are on a mission to clean the medication aisle. Johnson and Spielberg realized they weren’t happy with the ingredients in their children’s medications and worked with a team of medical professionals to transform the over-the-counter industry by making clean products.

Genexa products have the same effective active ingredients as conventional over-the-counter drugs – ingredients that offer therapeutic or medicinal value and have undergone years of scientific testing to ensure safety. The difference is in the inactive ingredients.

Because Genexa only uses clean inactive ingredients, families get drugs without artificial additives and common allergens – drugs that won’t have any of the potentially unwanted side effects that can accompany unnecessary synthetic ingredients in conventional drugs. Genexa is reinventing the way conventional pharmaceutical drugs are made, focusing on delivering the exact same OTC drugs without potentially harmful fillers contained in their inactive ingredients. Genexa does not seek to subvert conventional pharmaceutical medicine; rather, they focus on delivering the exact same OTC drugs without the potentially harmful fillers contained in their inactive ingredients.

Johnson and Spielberg believe that drugs can be effective and clean; people deserve better, and that’s why they created Genexa – real medicine, made clean.

Genexa

Genexa’s medical team has formulated a clean drug line that sets a new standard in the OTC industry

From the start, Johnson and Spielberg sought out experienced healthcare professional partners. These partners now form the Genexa Medical Advisory Board, a team of leading experts who have played a fundamental role in advancing healthcare in their fields. With these healthcare professionals and the expertise of people like Brian Perkins, president of Genexa and former global president of Consumer Pharmaceuticals & Nutritionals at Johnson & Johnson, Genexa has successfully launched clean over-the-counter drugs in many categories including allergies, pain and fever, colds and coughs. and digestion.

They have spent years doing extensive research and development, creating cutting edge technology to remove unnecessary synthetics and potential toxins from their formulas. The medical team has formulated a line of clean drugs that sets a new standard in the OTC industry.

Genexa breathes a breath of fresh air into the OTC industry and ensures that every family has access to the clean medicines they deserve.

These over the counter medications are exactly what you didn’t know you needed.

GMO-free, organic, gluten-free solutions designed to get everyone better

Genexa finally makes it possible to have both effective active ingredients and clean formulas. Genexa drugs are available at major retailers like Target, Walmart, Walgreens, CVS, Kroger, and Whole Foods, as well as at Genexa.com. If you order directly from their site, you will find clean medicine cabinet sets to choose from so kids and adults can easily refuel.

With active ingredients like acetaminophen and inactive ingredients like organic blueberry flavor and citrus extract, the Pain and fever in children drug from Genexa is obvious to have at home, with the Cough and congestion in children and the Immune support for children. If you are looking for clean medicines for your child’s symptoms, Genexa has some clean products that you should have in your medicine cabinet.

Genexa is the only clean medicine company that has removed inactive artificial ingredients from its products, such as propylene glycol, sorbitol, wheat starch, stearyl alcohol, sodium benzoate and disodium EDTA. This means that parents can feel better about what they are giving their children.

With Genexa, people know they are looking for medicines that will help them and their children safely.

You can also create your own personalized cleaning doctor’s office on Genexa.com. With the ability to mix and match clean medications and create a personalized set for the whole family, Genexa gives everyone the ability to bring home exactly what they need.

Genexa makes sure people get the quality products they deserve. Their line includes organic, vegan, gluten-free, and designed medicines to keep everyone improving.

Find the solutions you deserve with Genexa.

Genexa’s mission is to create a more socially and environmentally just world.

Genexa does not stop there. With the launch of their new blog of healthcare resources and guides, their commitment to wellness with impact partners and their sustainable suppliers, they strive to change more than there is in your medicine cabinet.

Genexa is launching a knowledge base that will contain hundreds of resources on common health issues, provide insight into symptoms, causes and treatments, and point people in the right direction when it comes to treating their symptoms.

By partnering with organizations like Thirst Project, Vitamin Angels and March of Dimes, Genexa is also committed to bringing well-being to all. By partnering with Thirst Project, Genexa has helped fund the construction of wells in several locations in El Salvador and brought clean, uncontaminated water to the communities of Lotificación San Alfredo, Cangrejera and La Libertad.

While working with Vitamin Angels and March of Dimes, Genexa has donated to life-saving charities to provide moms and babies with healthy medicine and healthy starts.

Genexa’s commitment does not stop there, they are also committed to the planet. Genexa works with companies that are dedicated to sustainable sourcing and has a number of certifications from organizations such as the Sustainable Forestry Initiative and USDA Certified Biobased Product approved renewable packaging. Genexa is also a B certified company and its mission is to create a more socially and environmentally just world.

Genexa is there to help families choose cleanliness.

Genexa
Genexa

There has never been a better time to know exactly what is going on in our body

It’s not every day that a business shows up and opens our eyes to the truth, and with medicine it’s never happened before. Genexa is the only clean drugs company in the OTC industry that is showing everyone that they have a different kind of choice, which they see as a healthier choice.

When families realize that Genexa is giving them drugs with the same effective active ingredients and only clean inactive ingredients, there is no other option that makes sense. Genexa is forever changing the drug aisle.

David Johnson and Max Spielberg believe parents around the world deserve the peace of mind that Genexa offers, and that’s because they are parents themselves. No more worries, questions or “What does this ingredient do?” While standing in the medication aisle trying to find a solution as soon as possible.

There has never been a better time to find out exactly what is going on in our body. Clean medicine is calling, it’s time to pick up the phone and go home to our loved ones.

Disclaimer: While we work to ensure that product information is correct, manufacturers may occasionally change their ingredient lists, packaging, products, product images and / or declared results or visuals. We recommend that you always read labels, warnings, and instructions before using or consuming any product. The content on this site is not intended to replace advice given by a physician, pharmacist or other licensed healthcare professional. The information and statements are not intended to diagnose, treat, cure or prevent any disease or health problem. For more information about a product, please contact the manufacturer. Us Weekly assumes no responsibility for any inaccuracies or inaccuracies in the products.

This article is brought to you by the Shop With Us team at Us Weekly. The Shop With Us team aims to highlight products and services that our readers might find interesting and useful, such as face masks, self-tanners, Lululemon style leggings, and all the best gifts for everyone in your life. . The selection of products and services, however, is in no way intended to constitute an endorsement by Us Weekly or any celebrity mentioned in the post.

The Shop With Us team can receive products from manufacturers for free to test. Additionally, Us Weekly receives compensation from the manufacturer of the products we write about when you click a link and then purchase the product featured in an article. It does not determine whether a product or service is featured or recommended. Shop With Us operates independently of the advertising sales team. We appreciate your feedback at ShopWithUs@usmagazine.com. Good shopping!

Source link

]]>
https://clomipheneqb.com/meet-the-founders-of-genexa-the-1st-clean-medicine-company/feed/ 0